Immunotherapeutic strategies for malignant glioma.
Immunotherapeutic strategies for malignant glioma.
复制标题
DOI：
10.1177/107327480401100306
复制
发表时间：
2004-05
期刊：
影响因子：
--
通讯作者：
R. Fenstermaker;M. Ciesielski
中科院分区：
文献类型：
--
作者：
R. Fenstermaker;M. Ciesielski
背景尽管手术、放疗和化疗取得了进展，但恶性神经胶质瘤患者的生存率仅取得了适度的改善。方法 作者回顾了神经胶质瘤的免疫学方面、潜在的治疗靶点以及围绕当前针对恶性神经胶质瘤的免疫治疗策略的问题。结果血脑屏障和所谓的大脑免疫特权并不一定是脑肿瘤有效免疫治疗不可克服的障碍。临床前研究提出了许多潜在的治疗途径。转化研究有望提供有关神经系统免疫运输的大量新信息，并提出恶性胶质瘤免疫治疗最有效的方法。结论 恶性胶质瘤需要更有效的辅助治疗。免疫学方法在治疗这些肿瘤中的适用性值得继续研究。
BACKGROUND Despite advances in surgery, radiation therapy, and chemotherapy, only modest improvement has been achieved in the survival of patients with malignant gliomas. METHODS The authors review the immunologic aspects of gliomas, potential targets for therapy, and issues surrounding current immunotherapeutic strategies directed against malignant gliomas. RESULTS The blood-brain barrier and the purported immunological privilege of the brain are not necessarily insurmountable obstacles to effective immunotherapy for brain tumors. Preclinical studies suggest a number of potential therapeutic avenues. Translational studies offer the prospect of providing substantial new information about immunological trafficking in the nervous system and suggesting the most fruitful approaches to immunotherapy for malignant gliomas. CONCLUSIONS More effective adjuvant treatments for malignant gliomas are needed. The applicability of immunological approaches in the treatment of these tumors warrants continued study.